PRME250516C1000
- 0.00
- 0.000.00%
Prime Medicine Newsroom
Prime Drink Group to Oppose Lenders' Move to Appoint a Receiver for Its Triani Canada Unit
Cantor Analysts Call for RFK Jr. Replacement Following Ousting of Marks at FDA
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
Prime Medicine Is Maintained at Buy by Chardan Capital
Prime Medicine Price Target Raised to $16 From $15 at Chardan
Why Prime Medicine Stock Is Soaring Today
Prime Medicine, Inc.: Promising Future in Gene Editing With Innovative AATD Program and Strategic Growth Potential
Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $14
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating
Prime Medicine Advances AATD Program With Promising Preclinical Results
Prime Medicine Launches Preclinical Program for Liver Treatments
Prime Medicine Announces Preclinical Program for Alpha-1 Antitrypsin Deficiency Utilizing Prime Editing Technology
Prime Medicine Unveiled A Preclinical Program For The Treatment Of Alpha-1 Antitrypsin Deficiency, The Next Program Within Its Liver Franchise. Prime Medicine Expects To File An Investigational New Drug And/Or Clinical Trial Application In Mid-2026
Express News | Prime Medicine Inc: Expects to File Ind and/or Cta in Mid-2026
Express News | Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Prime Medicine Price Target Maintained With a $10.00/Share by Citizens Capital Markets
JMP Securities Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10